BRPI0418074B8 - derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos - Google Patents
derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticosInfo
- Publication number
- BRPI0418074B8 BRPI0418074B8 BRPI0418074A BRPI0418074A BRPI0418074B8 BR PI0418074 B8 BRPI0418074 B8 BR PI0418074B8 BR PI0418074 A BRPI0418074 A BR PI0418074A BR PI0418074 A BRPI0418074 A BR PI0418074A BR PI0418074 B8 BRPI0418074 B8 BR PI0418074B8
- Authority
- BR
- Brazil
- Prior art keywords
- amide derivative
- bcr
- tyrosine kinase
- abl tyrosine
- pharmaceutical composition
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title abstract 4
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
- 229940125833 compound 23 Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
derivado de amida e medicamento. a presente invenção refere-se a um derivado de amida tendo excelente atividade inibitória da tirosina cinase bcr-abl, ou um sal do mesmo. a presente invenção fornece um derivado de amida representa pela fórmula geral (1) a seguir: [composto químico 23] [1] [6] (onde r1 representa -ch2-r12 etc.; r2 representa alquila, halogênio, haloalquila, etc.; r3 representa hidrogênio, etc.; het1 representa um grupo da fórmula [6] acima, etc.; e het2 representa pirimidinila, etc.) ou um sal farmaceuticamente aceitável do mesmo, e uma composição farmacêutica compreendendo o mesmo como um ingrediente ativo. o composto da presente invenção é útil como inibidor da tirosina cinase bcr-abl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-431398 | 2003-12-25 | ||
| JP2003431398 | 2003-12-25 | ||
| PCT/JP2004/019553 WO2005063709A1 (ja) | 2003-12-25 | 2004-12-27 | アミド誘導体及び医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0418074A BRPI0418074A (pt) | 2007-04-17 |
| BRPI0418074B1 BRPI0418074B1 (pt) | 2019-06-18 |
| BRPI0418074B8 true BRPI0418074B8 (pt) | 2021-05-25 |
Family
ID=34736430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418074A BRPI0418074B8 (pt) | 2003-12-25 | 2004-12-27 | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7728131B2 (pt) |
| EP (2) | EP1702917B1 (pt) |
| JP (3) | JPWO2005063709A1 (pt) |
| KR (1) | KR100848067B1 (pt) |
| CN (2) | CN100526298C (pt) |
| AU (1) | AU2004309248B2 (pt) |
| BR (1) | BRPI0418074B8 (pt) |
| CA (1) | CA2551529C (pt) |
| CY (1) | CY1120169T1 (pt) |
| DK (1) | DK1702917T3 (pt) |
| ES (1) | ES2651615T3 (pt) |
| HU (1) | HUE034712T2 (pt) |
| LT (1) | LT1702917T (pt) |
| MX (1) | MXPA06007237A (pt) |
| PL (1) | PL1702917T3 (pt) |
| PT (1) | PT1702917T (pt) |
| RU (1) | RU2410375C9 (pt) |
| SI (1) | SI1702917T1 (pt) |
| WO (1) | WO2005063709A1 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| JP2007297306A (ja) * | 2006-04-28 | 2007-11-15 | Kaneka Corp | 光学活性３−（１−ピロリジニル）ピロリジンの製造法 |
| US8093259B2 (en) | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
| EP2094682A2 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| WO2011008788A1 (en) * | 2009-07-14 | 2011-01-20 | Dawei Zhang | Fluoro-substituted compounds as kinase inhibitors and methods of use thereof |
| CN104402860A (zh) * | 2010-05-19 | 2015-03-11 | 江苏豪森药业股份有限公司 | 甲磺酸伊马替尼中间体的制备方法 |
| CN102477009B (zh) * | 2010-11-23 | 2014-01-01 | 清华大学深圳研究生院 | 取代的（s）-苯甲磺酰基吡咯烷-3-氨基衍生物及其制备方法与应用 |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| FR2980477B1 (fr) * | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
| RU2014146993A (ru) | 2012-04-24 | 2016-06-10 | Чугаи Сейяку Кабусики Кайся | Производное хиназолиндиона |
| MX2014012991A (es) | 2012-04-24 | 2015-08-14 | Chugai Pharmaceutical Co Ltd | Derivado de benzamida. |
| CA2927830A1 (en) | 2013-10-23 | 2015-04-30 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CN104876879B (zh) * | 2015-04-14 | 2018-05-18 | 中国科学院合肥物质科学研究院 | 一种bcr-abl激酶抑制剂 |
| CN106187995A (zh) * | 2015-05-05 | 2016-12-07 | 天津国际生物医药联合研究院 | 含酰胺键杂环类化合物及其制备方法和应用 |
| AU2016283105C1 (en) * | 2015-06-26 | 2023-02-02 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| JP6994715B2 (ja) * | 2017-10-04 | 2022-02-04 | 国立大学法人京都大学 | Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| AU2020232755A1 (en) * | 2019-03-05 | 2021-11-04 | Hongyi & Associates LLC. | Compounds for treating neurodegenerative diseases and cancers |
| WO2021228983A1 (en) | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (pt) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| CN100343237C (zh) | 2002-06-28 | 2007-10-17 | 日本新药株式会社 | 酰胺衍生物及医药品 |
| MXPA05001277A (es) * | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| CA2523852A1 (en) * | 2003-04-28 | 2004-11-11 | Ab Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
| DE602004013792D1 (de) * | 2003-08-15 | 2008-06-26 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
-
2004
- 2004-12-27 WO PCT/JP2004/019553 patent/WO2005063709A1/ja not_active Ceased
- 2004-12-27 SI SI200432413T patent/SI1702917T1/en unknown
- 2004-12-27 AU AU2004309248A patent/AU2004309248B2/en not_active Expired
- 2004-12-27 KR KR1020067014770A patent/KR100848067B1/ko not_active Expired - Lifetime
- 2004-12-27 JP JP2005516694A patent/JPWO2005063709A1/ja active Pending
- 2004-12-27 HU HUE04807908A patent/HUE034712T2/hu unknown
- 2004-12-27 DK DK04807908.1T patent/DK1702917T3/da active
- 2004-12-27 MX MXPA06007237A patent/MXPA06007237A/es active IP Right Grant
- 2004-12-27 BR BRPI0418074A patent/BRPI0418074B8/pt active IP Right Grant
- 2004-12-27 CN CNB2004800390488A patent/CN100526298C/zh not_active Expired - Lifetime
- 2004-12-27 PL PL04807908T patent/PL1702917T3/pl unknown
- 2004-12-27 LT LTEP04807908.1T patent/LT1702917T/lt unknown
- 2004-12-27 PT PT48079081T patent/PT1702917T/pt unknown
- 2004-12-27 EP EP04807908.1A patent/EP1702917B1/en not_active Expired - Lifetime
- 2004-12-27 CA CA2551529A patent/CA2551529C/en not_active Expired - Lifetime
- 2004-12-27 ES ES04807908.1T patent/ES2651615T3/es not_active Expired - Lifetime
- 2004-12-27 CN CN2008101863474A patent/CN101456841B/zh not_active Expired - Fee Related
- 2004-12-27 EP EP17181712.5A patent/EP3299358A1/en not_active Withdrawn
- 2004-12-27 US US10/584,829 patent/US7728131B2/en not_active Expired - Lifetime
- 2004-12-27 RU RU2006126974A patent/RU2410375C9/ru active
-
2012
- 2012-01-24 JP JP2012012025A patent/JP2012121893A/ja active Pending
-
2014
- 2014-03-07 JP JP2014045116A patent/JP2014196291A/ja not_active Withdrawn
-
2017
- 2017-11-02 CY CY20171101144T patent/CY1120169T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418074A (pt) | derivado de amida e medicamento | |
| BR0312288A (pt) | Derivados de amidas | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
| BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
| TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| NO20071042L (no) | 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer | |
| BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
| DE60140814D1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
| FI950309A0 (fi) | Proliiniamidijohdannaisia | |
| HUP0203965A2 (en) | Indazole compounds and pharmaceutical compositions containing them | |
| BR112012033770A2 (pt) | novo derivado de nicotinamida ou sal do mesmo | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
| BR0309558A (pt) | Derivados de quinazolina e medicamentos | |
| DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| BR0115454A (pt) | Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável | |
| DE60137442D1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
| CY1112057T1 (el) | Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι | |
| NO20076037L (no) | Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler | |
| ATE325809T1 (de) | Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure | |
| ATE321550T1 (de) | Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung | |
| BR0009135A (pt) | Derivado de benzamida e medicamento que ocontém | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
| NO20076038L (no) | Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |